TELO — Telomir Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $75.89m
- $74.63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 118.03 | ||
| Price to Tang. Book | 118.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1903.91% | ||
| Return on Equity | -810.18% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 1.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 26th, 2021
- Public Since
- February 9th, 2024
- No. of Shareholders
- 108
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 29,762,671
- Address
- 900 West Platt Street, Suite 200, TAMPA, 33606
- Web
- https://telomirpharma.com/
- Phone
- +1 8138642562
- Auditors
- Salberg & Company, P.A.
Upcoming Events for TELO
Q2 2025 Telomir Pharmaceuticals Inc Earnings Release
Similar to TELO
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Telomir Pharmaceuticals share price?
As of Today at 23:37 UTC, shares in Telomir Pharmaceuticals are trading at $2.55. This share price information is delayed by 15 minutes.
How has the Telomir Pharmaceuticals share price performed this year?
Shares in Telomir Pharmaceuticals last closed at $2.55 and the price had moved by -62.5% over the past 365 days. In terms of relative price strength the Telomir Pharmaceuticals share price has underperformed the S&P500 Index by -65.39% over the past year.
What are the analyst and broker recommendations for Telomir Pharmaceuticals?
There is no consensus recommendation for this security.
Find out moreWhat is the Telomir Pharmaceuticals dividend yield?
Telomir Pharmaceuticals does not currently pay a dividend.
Does Telomir Pharmaceuticals pay a dividend?
Telomir Pharmaceuticals does not currently pay a dividend.
When does Telomir Pharmaceuticals next pay dividends?
Telomir Pharmaceuticals does not currently pay a dividend.
How do I buy Telomir Pharmaceuticals shares?
To buy shares in Telomir Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Telomir Pharmaceuticals?
As of the previous close price of $2.55, shares in Telomir Pharmaceuticals had a market capitalisation of $75.89m.
Where are Telomir Pharmaceuticals shares listed?
Here are the trading details for Telomir Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TELO
What kind of share is Telomir Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Telomir Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Telomir Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Telomir Pharmaceuticals is $15.25. That is 498.04% above the last closing price of $2.55.
Analysts covering Telomir Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.40 for the next financial year.
Find out moreWhat is the trend in the Telomir Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Telomir Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -39.47%.
As of the last closing price of $2.55, shares in Telomir Pharmaceuticals were trading -43.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Telomir Pharmaceuticals PE Ratio?
The Telomir Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Telomir Pharmaceuticals?
We do not have data on Telomir Pharmaceuticals' directors